Immune responses following DNA vaccination by needle-free injection against Burkholderia pseudomallei hemolysin co-regulated protein 1
Burkholderia pseudomallei is a facultative intracellular bacterium found in soil, which causes melioidosis, a disease with diverse symptomatology. B. pseudomallei is an emerging threat in the United States based on recent environmental samples and case reports. Acute infection is 10%–40% fatal depen...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1612540/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849434766844100608 |
|---|---|
| author | Michael L. Davies Sergei S. Biryukov Christopher P. Klimko Jennifer L. Dankmeyer Nathaniel O. Rill Melissa Hunter Christopher T. Braun Deven W. Patrick Tyrique D. David Steven A. Kwilas Carlos I. Rodriguez Brian A. Smith Ju Qiu Jay W. Hooper Christopher K. Cote |
| author_facet | Michael L. Davies Sergei S. Biryukov Christopher P. Klimko Jennifer L. Dankmeyer Nathaniel O. Rill Melissa Hunter Christopher T. Braun Deven W. Patrick Tyrique D. David Steven A. Kwilas Carlos I. Rodriguez Brian A. Smith Ju Qiu Jay W. Hooper Christopher K. Cote |
| author_sort | Michael L. Davies |
| collection | DOAJ |
| description | Burkholderia pseudomallei is a facultative intracellular bacterium found in soil, which causes melioidosis, a disease with diverse symptomatology. B. pseudomallei is an emerging threat in the United States based on recent environmental samples and case reports. Acute infection is 10%–40% fatal depending on treatment conditions. No vaccines for B. pseudomallei have been approved for human use, although several are under development, mostly targeting the antigens Hcp1 (hemolysin-coregulated protein 1) and CPS (capsular polysaccharide). For development of new vaccines, DNA compares favorably to other platforms in storage stability, low cost, and ease of design. Needle-free jet injection has been effective in immunizing against several infections in laboratory animals; the delivery devices are simple to use and have been FDA 510k cleared for human use. Herein, we developed a DNA vaccine targeting Hcp1 (pWRG/Hcp1) and delivered it to rabbits and mice by jet injection using a PharmaJet Stratis and a prototype adjustable-dose PharmaJet Tropis, respectively. The Hcp1 DNA vaccine was unadjuvanted and not combined with any other B. pseudomallei antigens. Immunization was followed by assessment of serum antibodies and cellular immunity against Hcp1 protein. Rabbits and mice showed induction of anti-Hcp1 antibodies after as few as two doses of pWRG/Hcp1, and splenocytes responsive to restimulation with Hcp1 protein were also detected after two doses. These results demonstrate the feasibility of inducing immunity against Hcp1 of B. pseudomallei using DNA alone. These results also serve as a proof-of-concept for immunizing mice with a PharmaJet device previously only used for larger animals. |
| format | Article |
| id | doaj-art-dde386f4221e40b494eb7f4a77683bad |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-dde386f4221e40b494eb7f4a77683bad2025-08-20T03:26:31ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-06-011610.3389/fimmu.2025.16125401612540Immune responses following DNA vaccination by needle-free injection against Burkholderia pseudomallei hemolysin co-regulated protein 1Michael L. Davies0Sergei S. Biryukov1Christopher P. Klimko2Jennifer L. Dankmeyer3Nathaniel O. Rill4Melissa Hunter5Christopher T. Braun6Deven W. Patrick7Tyrique D. David8Steven A. Kwilas9Carlos I. Rodriguez10Brian A. Smith11Ju Qiu12Jay W. Hooper13Christopher K. Cote14Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, United StatesBacteriology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, United StatesBacteriology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, United StatesBacteriology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, United StatesBacteriology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, United StatesBacteriology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, United StatesBacteriology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, United StatesBacteriology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, United StatesBacteriology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, United StatesVirology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, United StatesBacteriology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, United StatesBacteriology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, United StatesBiostatistics Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, United StatesVirology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, United StatesBacteriology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, United StatesBurkholderia pseudomallei is a facultative intracellular bacterium found in soil, which causes melioidosis, a disease with diverse symptomatology. B. pseudomallei is an emerging threat in the United States based on recent environmental samples and case reports. Acute infection is 10%–40% fatal depending on treatment conditions. No vaccines for B. pseudomallei have been approved for human use, although several are under development, mostly targeting the antigens Hcp1 (hemolysin-coregulated protein 1) and CPS (capsular polysaccharide). For development of new vaccines, DNA compares favorably to other platforms in storage stability, low cost, and ease of design. Needle-free jet injection has been effective in immunizing against several infections in laboratory animals; the delivery devices are simple to use and have been FDA 510k cleared for human use. Herein, we developed a DNA vaccine targeting Hcp1 (pWRG/Hcp1) and delivered it to rabbits and mice by jet injection using a PharmaJet Stratis and a prototype adjustable-dose PharmaJet Tropis, respectively. The Hcp1 DNA vaccine was unadjuvanted and not combined with any other B. pseudomallei antigens. Immunization was followed by assessment of serum antibodies and cellular immunity against Hcp1 protein. Rabbits and mice showed induction of anti-Hcp1 antibodies after as few as two doses of pWRG/Hcp1, and splenocytes responsive to restimulation with Hcp1 protein were also detected after two doses. These results demonstrate the feasibility of inducing immunity against Hcp1 of B. pseudomallei using DNA alone. These results also serve as a proof-of-concept for immunizing mice with a PharmaJet device previously only used for larger animals.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1612540/fullmelioidosisBurkholderia pseudomalleivaccinesDNA vaccinesneedle-free injectionmice |
| spellingShingle | Michael L. Davies Sergei S. Biryukov Christopher P. Klimko Jennifer L. Dankmeyer Nathaniel O. Rill Melissa Hunter Christopher T. Braun Deven W. Patrick Tyrique D. David Steven A. Kwilas Carlos I. Rodriguez Brian A. Smith Ju Qiu Jay W. Hooper Christopher K. Cote Immune responses following DNA vaccination by needle-free injection against Burkholderia pseudomallei hemolysin co-regulated protein 1 Frontiers in Immunology melioidosis Burkholderia pseudomallei vaccines DNA vaccines needle-free injection mice |
| title | Immune responses following DNA vaccination by needle-free injection against Burkholderia pseudomallei hemolysin co-regulated protein 1 |
| title_full | Immune responses following DNA vaccination by needle-free injection against Burkholderia pseudomallei hemolysin co-regulated protein 1 |
| title_fullStr | Immune responses following DNA vaccination by needle-free injection against Burkholderia pseudomallei hemolysin co-regulated protein 1 |
| title_full_unstemmed | Immune responses following DNA vaccination by needle-free injection against Burkholderia pseudomallei hemolysin co-regulated protein 1 |
| title_short | Immune responses following DNA vaccination by needle-free injection against Burkholderia pseudomallei hemolysin co-regulated protein 1 |
| title_sort | immune responses following dna vaccination by needle free injection against burkholderia pseudomallei hemolysin co regulated protein 1 |
| topic | melioidosis Burkholderia pseudomallei vaccines DNA vaccines needle-free injection mice |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1612540/full |
| work_keys_str_mv | AT michaelldavies immuneresponsesfollowingdnavaccinationbyneedlefreeinjectionagainstburkholderiapseudomalleihemolysincoregulatedprotein1 AT sergeisbiryukov immuneresponsesfollowingdnavaccinationbyneedlefreeinjectionagainstburkholderiapseudomalleihemolysincoregulatedprotein1 AT christopherpklimko immuneresponsesfollowingdnavaccinationbyneedlefreeinjectionagainstburkholderiapseudomalleihemolysincoregulatedprotein1 AT jenniferldankmeyer immuneresponsesfollowingdnavaccinationbyneedlefreeinjectionagainstburkholderiapseudomalleihemolysincoregulatedprotein1 AT nathanielorill immuneresponsesfollowingdnavaccinationbyneedlefreeinjectionagainstburkholderiapseudomalleihemolysincoregulatedprotein1 AT melissahunter immuneresponsesfollowingdnavaccinationbyneedlefreeinjectionagainstburkholderiapseudomalleihemolysincoregulatedprotein1 AT christophertbraun immuneresponsesfollowingdnavaccinationbyneedlefreeinjectionagainstburkholderiapseudomalleihemolysincoregulatedprotein1 AT devenwpatrick immuneresponsesfollowingdnavaccinationbyneedlefreeinjectionagainstburkholderiapseudomalleihemolysincoregulatedprotein1 AT tyriqueddavid immuneresponsesfollowingdnavaccinationbyneedlefreeinjectionagainstburkholderiapseudomalleihemolysincoregulatedprotein1 AT stevenakwilas immuneresponsesfollowingdnavaccinationbyneedlefreeinjectionagainstburkholderiapseudomalleihemolysincoregulatedprotein1 AT carlosirodriguez immuneresponsesfollowingdnavaccinationbyneedlefreeinjectionagainstburkholderiapseudomalleihemolysincoregulatedprotein1 AT brianasmith immuneresponsesfollowingdnavaccinationbyneedlefreeinjectionagainstburkholderiapseudomalleihemolysincoregulatedprotein1 AT juqiu immuneresponsesfollowingdnavaccinationbyneedlefreeinjectionagainstburkholderiapseudomalleihemolysincoregulatedprotein1 AT jaywhooper immuneresponsesfollowingdnavaccinationbyneedlefreeinjectionagainstburkholderiapseudomalleihemolysincoregulatedprotein1 AT christopherkcote immuneresponsesfollowingdnavaccinationbyneedlefreeinjectionagainstburkholderiapseudomalleihemolysincoregulatedprotein1 |